UBS Group’s Cellyan Biotechnology HKPD Stock Holding History

UBS Group’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63	Sell	110 -1,426	-93%	-$1.04K	﹤0.01%	10179
2025 Q4	$1.27K	Buy	1,536 +1,438	+1,467%	+$1.54K	﹤0.01%	9645
2025 Q3	$144	Sell	98 -20,777	-100%	-$26.6K	﹤0.01%	9870
2025 Q2	$26.7K	Buy	20,875 +20,603	+7,575%	+$25.5K	﹤0.01%	8248
2025 Q1	$294	Buy	+272	New	+$480	﹤0.01%	9847

Other funds holding HKPD

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's HKPD Position: Q1 2026 in Review

UBS Group reduced its Cellyan Biotechnology (HKPD) stake by 93% in Q1 2026, selling an estimated $1.04K and leaving 110 shares worth $63. The position accounts for ﹤0.01% of the portfolio, ranked #10179.

UBS Group first reported a position in HKPD in Q1 2025 and has held it in 5 quarters since. The position peaked at $26.7K in Q2 2025. 4 funds tracked by Wall St. Rank hold HKPD as of Q1 2026.

UBS Group held 110 shares of Cellyan Biotechnology worth $63 as of Q1 2026.
UBS Group sold 1,426 Cellyan Biotechnology shares in Q1 2026, an estimated $1.04K.
Cellyan Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10179 holding.
UBS Group first reported a position in Cellyan Biotechnology in Q1 2025 and has held it in 5 quarters since.
UBS Group's Cellyan Biotechnology position peaked at $26.7K in Q2 2025.
4 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.